BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30928650)

  • 41. Mutations in ABL kinase domain are associated with inferior progression-free survival.
    Sharma P; Mohanty S; Kochupillai V; Kumar L
    Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.
    Rostami G; Hamid M; Yaran M; Khani M; Karimipoor M
    J Hum Genet; 2015 May; 60(5):253-8. PubMed ID: 25740611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S; Zammit V; Vitale SR; Pennisi MS; Massimino M; Tirrò E; Forte S; Spitaleri A; Antolino A; Siracusa S; Accurso V; Mannina D; Impera S; Musolino C; Russo S; Malato A; Mineo G; Musso M; Porretto F; Martino B; Di Raimondo F; Manzella L; Vigneri P; Stagno F
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31064152
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
    Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Kantarjian H; O'Brien S; Shan J; Huang X; Garcia-Manero G; Faderl S; Ravandi-Kashani F; Verstovsek S; Beth Rios M; Cortes J
    Cancer; 2008 Feb; 112(4):837-45. PubMed ID: 18085610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
    Goldman J
    Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
    Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP
    Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
    Soverini S; de Benedittis C; Mancini M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.
    Ono T; Miyawaki S; Kimura F; Kanamori H; Ohtake S; Kitamura K; Fujita H; Sugiura I; Usuki K; Emi N; Tamaki S; Aoyama Y; Kaya H; Naoe T; Tadokoro K; Yamaguchi T; Ohno R; Ohnishi K;
    Leuk Res; 2011 May; 35(5):598-603. PubMed ID: 21239056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.
    Chahardouli B; Zaker F; Mousavi SA; Kazemi A; Ostadali M; Nadali F; Rostami S; Alimoghaddam K; Ghavamzade A
    Hematology; 2013 May; 18(3):158-62. PubMed ID: 23540562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
    Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
    Bengió RM; Riva ME; Moiraghi B; Lanari E; Milone J; Ventriglia V; Bullorsky E; Tezanos Pinto Md; Murro H; Bianchini M; Larripa I
    Leuk Lymphoma; 2011 Sep; 52(9):1720-6. PubMed ID: 21663510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
    Romzova M; Smitalova D; Tom N; Jurcek T; Culen M; Zackova D; Mayer J; Racil Z
    Br J Haematol; 2020 May; 189(3):469-474. PubMed ID: 32037516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Additional cytogenetic abnormalities in chronic myeloid leukaemia; an experience from Pakistan.
    Anwar N; Nadeem M; Khurram S; Fatima N; Shamsi T
    J Pak Med Assoc; 2021 Feb; 71(2(B)):633-635. PubMed ID: 33941949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia.
    Costa HZ; Pereira NF; Kaminski L; Pasquini R; Funke VAM; Mion ALV
    Hematol Transfus Cell Ther; 2018; 40(4):363-367. PubMed ID: 30370415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.